Tevimbra 100 mg concentrate for solution for infusion
Sponsors
Solti Group, Oslo University Hospital HF, Unicancer, Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, University Hospital Of Clermont-Ferrand
Conditions
ALBI grade 1 or 2 liver functionAdvanced/Metastatic Non-squamous Non-Small Cell Lung CancerAdvanced/metastatic colorectal cancerCancerColorectal cancerLocally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMetastatic Colorectal Cancer without liver metastasesMetastatic disease
Phase 1
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
RecruitingCTIS2025-520743-33-00
Start: 2025-07-23Target: 69Updated: 2025-07-21
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
Not yet recruitingCTIS2025-521989-95-00
Target: 88Updated: 2025-12-12
Phase 2
HESTIA : A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function Score.
RecruitingCTIS2024-516443-57-00
Start: 2023-10-11Target: 50Updated: 2025-08-22
SOLTI-1904: EfficACy of tislelizumab and spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial)
CompletedCTIS2023-508549-41-00
Start: 2021-04-30End: 2025-07-31Target: 184Updated: 2025-05-19
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.
RecruitingCTIS2024-513779-42-02
Start: 2025-03-27Target: 100Updated: 2025-10-10
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
RecruitingCTIS2024-519205-35-01
Start: 2025-07-08Target: 30Updated: 2025-09-10
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal squamous-cell carcinoma
RecruitingCTIS2024-518358-17-00
Start: 2025-10-06Target: 95Updated: 2025-04-17
– IKF/AIO-QUINTIS –
A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
RecruitingCTIS2024-519929-38-00
Start: 2025-10-27Target: 140Updated: 2025-10-27
FUTURE platform trial –
A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
RecruitingCTIS2024-517573-24-00
Start: 2025-12-08Target: 33Updated: 2025-12-02
Phase 3
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA
Active, not recruitingCTIS2023-508828-35-01
Start: 2022-03-28Target: 316Updated: 2025-06-20
A Phase 3, Multi-center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingCTIS2025-522862-58-00
Start: 2025-12-29Target: 63Updated: 2025-11-19